These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 11750838

  • 1. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate.
    Dooley MJ, Poole SG, Rischin D, Webster LK.
    Eur J Cancer; 2002 Jan; 38(1):44-51. PubMed ID: 11750838
    [Abstract] [Full Text] [Related]

  • 2. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K.
    Cancer Chemother Pharmacol; 1998 Jan; 42(4):307-12. PubMed ID: 9744776
    [Abstract] [Full Text] [Related]

  • 3. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
    Nagao S, Fujiwara K, Imafuku N, Kagawa R, Kozuka Y, Oda T, Maehata K, Ishikawa H, Koike H, Aotani E, Kohno I.
    Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
    [Abstract] [Full Text] [Related]

  • 4. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
    Donahue A, McCune JS, Faucette S, Gillenwater HH, Kowalski RJ, Socinski MA, Lindley C.
    Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
    [Abstract] [Full Text] [Related]

  • 5. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.
    Shepherd ST, Gillen G, Morrison P, Forte C, Macpherson IR, White JD, Mark PB.
    Eur J Cancer; 2014 Mar; 50(5):944-52. PubMed ID: 24445148
    [Abstract] [Full Text] [Related]

  • 6. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort.
    Cathomas R, Klingbiel D, Geldart TR, Mead GM, Ellis S, Wheater M, Simmonds P, Nagaraj N, von Moos R, Fehr M.
    Ann Oncol; 2014 Aug; 25(8):1591-7. PubMed ID: 24669017
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
    de Lemos ML, Hsieh T, Hamata L, Levin A, Swenerton K, Djurdjev O, Vu T, Hu F, Conklin J, Malfair Taylor SC.
    Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
    [Abstract] [Full Text] [Related]

  • 8. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
    Morrow A, Garland C, Yang F, De Luna M, Herrington JD.
    J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
    [Abstract] [Full Text] [Related]

  • 9. Flat dosing of carboplatin is justified in adult patients with normal renal function.
    Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH.
    Clin Cancer Res; 2006 Nov 01; 12(21):6502-8. PubMed ID: 17085665
    [Abstract] [Full Text] [Related]

  • 10. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
    Herrington JD, Tran HT, Riggs MW.
    Cancer Chemother Pharmacol; 2006 Jan 01; 57(2):241-7. PubMed ID: 16133538
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
    Ekhart C, Rodenhuis S, Schellens JH, Beijnen JH, Huitema AD.
    Cancer Chemother Pharmacol; 2009 Jun 01; 64(1):115-22. PubMed ID: 18989671
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.
    van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH.
    Cancer Chemother Pharmacol; 1996 Jun 01; 37(3):266-70. PubMed ID: 8529288
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer.
    Shimokata T, Ando Y, Yasuda Y, Hamada A, Kawada K, Saito H, Matsuo S, Kondo M, Imaizumi K, Hasegawa Y.
    Cancer Sci; 2010 Dec 01; 101(12):2601-5. PubMed ID: 20860621
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.